Identification of an estrogen-regulated circadian mechanism necessary for breast acinar morphogenesis

Cell Cycle

Volumn 11, Issue 19, 2012, Pages 3691-3700

  Rossetti, Stefano ^a   Corlazzoli, Francesca ^a   Gregorski, Alex ^a   Azmi, Nurul Hidayah A ^a   Sacchi, Nicoletta ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

3D acinar morphogenesis; BMAL1; Breast epithelial cells; Circadian clock; Estrogen; Estrogen receptor alpha (ERA); PER2

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA;

ACINAR CELL; ARTICLE; BMAL1 GENE; BREAST CANCER; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER CELL; CIRCADIAN RHYTHM; CONTROLLED STUDY; CULTURE TECHNIQUE; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HORMONAL REGULATION; HUMAN; HUMAN CELL; MORPHOGENESIS; PER2 GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84867256156     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21946     Document Type: Article

References (42)

1. Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci 2003; 24:479-85; PMID:12967773; http://dx.doi.org/10.1016/S0165-6147(03)00229-3.
2. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002; 4:197-201; PMID:12223124; http://dx.doi.org/10.1186/bcr452.
3. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87:905-31; PMID:17615392; http://dx.doi.org/10.1152/physrev.00026.2006.
4. Welboren WJ, Stunnenberg HG, Sweep FC, Span PN. Identifying estrogen receptor target genes. Mol Oncol 2007; 1:138-43; PMID:19383291; http://dx.doi.org/10.1016/j.molonc.2007.04.001.
5. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007; 3:e87; PMID:17542648; http://dx.doi.org/10.1371/journal.pgen.0030087.
6. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol 2010; 6:456; PMID:21179027; http://dx.doi.org/ 10.1038/msb.2010.109.
7. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009; 462:58-64; PMID:19890323; http://dx.doi.org/10.1038/nature08497.
8. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, et al. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 2009; 28:1418-28; PMID:19339991; http://dx.doi.org/10.1038/emboj.2009.88.
9. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147:5557-63; PMID:16946015; http://dx.doi.org/10.1210/en.2006-0729.
10. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Mol Endocrinol 2005; 19:833-42; PMID:15695368; http://dx.doi.org/10.1210/me.2004- 0486.
11. Ohshiro K, Schwartz AM, Levine PH, Kumar R. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One 2012; 7:e30725; PMID:22295107; http://dx.doi.org/10.1371/journal.pone. 0030725.
12. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010; 24:709-21; PMID:20197310; http://dx.doi.org/10. 1210/me.2009-0317.
13. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307:1625-30; PMID:15705806; http://dx.doi.org/10.1126/science. 1106943.
14. Li Q, Zheng T, Holford TR, Boyle P, Zhang Y, Dai M. Light at night and breast cancer risk: results from a population-based case-control study in Connecticut, USA. Cancer Causes Control 2010; 21:2281-5; PMID:20927578; http://dx.doi.org/10.1007/s10552-010-9653-z.
15. Leonardi GC, Rapisarda V, Marconi A, Scalisi A, Catalano F, Proietti L, et al. Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). [Review]. Oncol Rep 2012; 28:418-28; PMID:22664950.
16. Menegaux F, Truong T, Anger A, Cordina-Duverger E, Lamkarkach F, Arveux P, et al. Night work and breast cancer: A population-based case-control study in France (the CECILE study). Int J Cancer 2012; PMID:22689255; http://dx.doi.org/10.1002/ijc.27669.
17. Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control 2006; 17:531-7; PMID:16596307; http://dx.doi.org/10.1007/s10552-005-9006-5.
18. Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control 2006; 17:539-45; PMID:16596308; http://dx.doi.org/10.1007/s10552-005-9010-9.
19. Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol 2009; 38:963-70; PMID:19380369; http://dx.doi.org/10.1093/ije/dyp178.
20. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72:517-49; PMID:20148687; http://dx.doi.org/10.1146/annurev-physiol- 021909-135821.
21. Rossetti S, Esposito J, Corlazzoli F, Gregorski A, Sacchi N. Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes. Cell Cycle 2012; 11:350-60; PMID:22193044; http://dx.doi.org/10.4161/cc.11.2.18792.
22. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007; 26:7916-20; PMID:17599055; http://dx.doi.org/10.1038/sj.onc.1210585.
23. Schmutz I, Ripperger JA, Baeriswyl-Aebischer S, Albrecht U. The mammalian clock component PERIOD2 coordinates circadian output by interaction with nuclear receptors. Genes Dev 2010; 24:345-57; PMID:20159955; http://dx.doi.org/10.1101/gad.564110.
24. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 2005; 16:254-8; PMID:15703542; http://dx.doi.org/10. 1097/01.ede.0000152525.21924.54.
25. Allred DC. The origins of oestrogen receptor negative breast cancer. Breast Cancer Res 2007; 9:S20; http://dx.doi.org/10.1186/bcr1818.
26. Elledge R, Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Harris J, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:601-17.
27. Masood S. Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol 1992; 8:475-91; PMID:1396026; http://dx.doi.org/10.1002/dc.2840080508.
28. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 2007; 4:516-25; PMID:17728710; http://dx.doi.org/10.1038/ncponc0908.
29. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001; 8:47-61; PMID:11350726; http://dx.doi.org/10.1677/erc.0.0080047.
30. Laganière J, Deblois G, Giguère V. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol 2005; 19:1584-92; PMID:15831516; http://dx.doi.org/10.1210/me.2005-0040.
31. Balsalobre A. Clock genes in mammalian peripheral tissues. Cell Tissue Res 2002; 309:193-9; PMID:12111549; http://dx.doi.org/10.1007/s00441-002-0585-0.
32. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418:935-41; PMID:12198538; http://dx.doi.org/10.1038/nature00965.
33. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003; 3:350-61; PMID:12724733; http://dx.doi.org/10.1038/nrc1072.
34. Canaple L, Kakizawa T, Laudet V. The days and nights of cancer cells. Cancer Res 2003; 63:7545-52; PMID:14633665.
35. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006; 66:3903-11; PMID:16585219; http://dx.doi.org/10.1158/0008-5472.CAN-05- 4363.
36. Yan L, Yang X, Davidson NE. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 2001; 6:183-92; PMID:11501578; http://dx.doi.org/10.1023/A: 1011308707512.
37. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54:2552-5; PMID:8168078.
38. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998; 93:929-37; PMID:9635423; http://dx.doi.org/10.1016/S0092-8674(00)81199-X.
39. Ueda HR, Chen W, Adachi A, Wakamatsu H, Hayashi S, Takasugi T, et al. A transcription factor response element for gene expression during circadian night. Nature 2002; 418:534-9; PMID:12152080; http://dx.doi.org/10.1038/ nature00906.
40. Akashi M, Takumi T. The orphan nuclear receptor RORalpha regulates circadian transcription of the mammalian core-clock Bmal1. Nat Struct Mol Biol 2005; 12:441-8; PMID:15821743; http://dx.doi.org/10.1038/nsmb925.
41. Rossetti S, Hoogeveen AT, Esposito J, Sacchi N. Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis. J Cell Mol Med 2010; 14(6A):1358-70; PMID:19961547; http://dx.doi.org/10.1111/j.1582-4934.2009.00982.x.
42. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-68; PMID:12798140; http://dx.doi.org/10.1016/ S1046-2023(03)00032-X.